Windonw

Window Therapeutics is a Boston-based biotechnology company focused on developing next-generation cancer therapeutics that expand the therapeutic window. The company utilizes its proprietary Bottle-brush-Analogue-Macromonomer (BAM) technology to engineer drugs that penetrate diseased tissue and target cancer cells while limiting damage to healthy cells. This platform, which originated from research at the Massachusetts Institute of Technology, allows for the creation of various drug conjugates, including small molecule and antibody-brush conjugates. Window Therapeutics' lead programs include a BAM-conjugated version of bortezomib for multiple myeloma and a pipeline of antibody-brush conjugates for solid and hematological malignancies. The company is supported by partnerships with the National Cancer Institute's Nanotechnology Characterization Laboratory and the AIM-HI Accelerator Fund.